Rhode Island College

Digital Commons @ RIC
Master's Theses, Dissertations, Graduate Research and Major Papers Overview
August 2022

Cancer Care Team Education and Oral Anticancer Medication
Adherence
Arielle Lee

Follow this and additional works at: https://digitalcommons.ric.edu/etd

Recommended Citation
Lee, Arielle, "Cancer Care Team Education and Oral Anticancer Medication Adherence" (2022). Master's
Theses, Dissertations, Graduate Research and Major Papers Overview. 406.
https://digitalcommons.ric.edu/etd/406

This Major Paper is brought to you for free and open access by Digital Commons @ RIC. It has been accepted for
inclusion in Master's Theses, Dissertations, Graduate Research and Major Papers Overview by an authorized
administrator of Digital Commons @ RIC. For more information, please contact digitalcommons@ric.edu.

1

CANCER CARE TEAM EDUCATION AND ORAL
ANTICANCER MEDICATION ADHERENCE

by
Arielle Lee
A Major Paper Submitted in Partial Fulfillment
of the Requirements for the Degree of
Master of Science in Nursing
in
The School of Nursing
Rhode Island College
2022

2
Cancer Care Team Education and Oral Anticancer Medication Adherence:
A Quality Improvement Project
Background/Statement of the Problem
Cancer treatment is constantly evolving with the advancement of medical
technology. The administration of chemotherapy drugs has shifted dramatically in the
past 15 years from parenteral infusion to oral administration, with oral cancer therapy
accounting for 10% of treatments in 2010 and rising to 25% of all cancer therapies in
2013 (Bellomo, 2016). Historically, the only treatment options were intravenous (IV)
chemotherapy, but with the development in medications, there are numerous oral
anticancer medications (OAM) available. Advances in oral therapies have not only
improved outcomes and survival in patients with cancer but also reduces the burden of
care by allowing for convenient dosing outside of the hospital without the need for nurse
administration and IV infusion (Greer et al., 2016). OAM offers many advantages to
patients, including autonomy and a sense of control over their disease, ease of
administration, and better quality of life, when compared to receiving traditional IV
chemotherapy (Divakaruni et. al., 2017). Although the chemotherapy is in a pill form, the
medication is comparatively as potent as IV chemotherapy with similar adverse sideeffects. Patients may prefer the convenience of taking their OAM in the comfort of their
own home rather than making frequent visits in the outpatient clinic, however, this may
lead to issues with adherence.
The World Health Organization (WHO) defines adherence as “the extent to which
a person’s behavior-taking medication, following a diet, and/or executing lifestyle
changes corresponds with agreed recommendations from a healthcare provider.”(World
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Health Organization, 2003, p. 17). Adherence is a complex phenomenon that is often
difficult to assess due to lack of gold standard measurement, and several barriers
influencing adherence. Nonadherence is defined as when patients intentionally or
unintentionally delay or do not start a prescribed medication, take less than the prescribed
dose, or stop taking a prescribed medication (World Health Organization, 2003, p. 18).
The standard of care for IV chemotherapy is for an oncology nurse to administer
the medication in an ambulatory setting. While the chemotherapy is infusing the patients
have an increased opportunity to ask disease related questions during their infusions. This
allows the nurse an opportunity to reinforce the importance of adherence to their
treatment and provide education on symptom management. During this interaction the
oncology nurse is closely monitoring for adverse side effects while performing an
oncology assessment. Since the administration of cancer treatment increasingly moves
from the hospital to the home, the cancer care team and their patients face new challenges
in ensuring optimal adherence to treatment. The responsibility of medication
administration is placed on the patient and or caregiver who often have limited or no
experience in healthcare.
A common misconception of OAM adherence is that cancer is a serious and lifethreatening disease, therefore one would expect a higher rate of medication adherence.
Although, the literature demonstrate patients may adjust their doses without informing
their healthcare provider. For example, some cancer patients may exhibit over-adherence
to self-administered medication, increasing the dose because of perceived ineffectiveness
or because they believe more is better (D’Amato, 2008). A patient is considered to be
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nonadherent if he or she misses doses, takes additional doses to those prescribed, or takes
doses either in the wrong quantity or at the wrong time (Tokdemir & Kav, 2017).
A systematic review of adherence to OAM by Greer et al. (2016) reported
adherence estimates ranged widely across studies from 46% to 100%. The consequences
of non-adherence include increased health care utilization; poor disease outcomes such
as, relapse and decreased survival time; and lack of patient satisfaction (Divakaruni et.
al., 2017). Inadequate adherence can result in a disruption of the therapeutic index of
drug needed to eradicate the cancer. Hence, it is critical to develop individualized
interventions that encourage patients to adhere to oral cancer chemotherapy and thus
increase their chances of survival (Schneider et al., 2014).
The transition of cancer treatment delivery from IV to OAM has led to issues with
adherence as the patient is self-administrating their OAM outside of the infusion center
with no nursing supervision. With the development of OAM, the cancer care team will
need to make practice changes to provide patients with the knowledge and support
necessary for safe administration, side effect monitoring and reporting safe drug
handling, and accurate dosing following medication specific guidelines (Matthews &
Caprera, 2014).
Within the context of cancer care, adherence to medication has become a high
priority given the development of new oral therapies in recent years and accumulating
evidence demonstrating poor adherence to these medications (Greer et al., 2016). The
American Society of Clinical Oncology (ASCO) and National Community Oncology
Dispensing Association (NCODA) standards for medically integrated dispensing were
developed by a multidisciplinary panel. The standards include evidence-based review of
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interventions to improve outcomes of patients who are being prescribed an OAM and
supportive care medication in an outpatient setting (Dillmon et al., 2019). The objective
of the patient-centered quality standards is to provide guidelines intended to optimize the
quality and safety of dispensing of OAM. The advancement of treatment demonstrates a
need to develop improved strategies for assessment, patient education, adverse side-effect
management, and ongoing monitoring of care.
The purpose of this quality improvement project is to evaluate and expand the
cancer care team’s knowledge on OAMs. The project will include a pretest to evaluate
the care team’s knowledge of OAMs. Next the participants will receive a focused review
of literature with an educational learning program derived from 2016 ASCO and
Oncology Nursing Society (ONS) administration safety standards (Neuss et al., 2017).,
followed by a post intervention test. The educational program will include three main
themes: oral chemotherapy, patient education and optimal medication adherence. The
learning objective for this quality improvement project is to provide an educational
learning program to further expand the cancer care team’s knowledge of OAMs by
identifying and implementing interventions that may enhance medication adherence, and
improve patient education based on current guidelines.
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Literature Review
The literature review was conducted using the CINAHL, Medline, Oncology
Nursing Society, Google Scholar, and PubMed. Key search terms included oral
chemotherapy, oral anticancer agent/therapies, adherence, medication adherence, patient
education, nursing intervention and multidisciplinary oncology team.
The State of Cancer in the United States
The American Society of Clinical Oncology defines cancer as the uncontrolled
growth of abnormal cells in the body. Cancer develops when the body’s normal control
mechanism stops working, as the old cells do not die and instead grow out of control,
forming new, abnormal cells in which form a mass of tissue, called a tumor. The article
state of cancer care in America reports there were more than 14 million cancer survivors
in 2014, and 1.7 million new diagnoses were expected in 2015. Cancer does not
discriminate as the disease will inflict patients from all different demographics including
race, age, gender, educational level, or socioeconomic status. In 2015, the United States
made significant improvements in cancer care, as evidenced by declining incidence and
mortality rates for many types of cancer, the growing number of new drugs and
technologies available to patients, and advancements in precision medicine (American
Society of Clinical Oncology, 2016).
As a result of the advancement in cancer care, millions of Americans who develop
and survive cancer will require long-term care and monitoring to detect and treat
recurrence or new cancers. They may also require support for long-term physical,
emotional, psychosocial, and financial adverse effects as a result of their treatment. Since,
the patients are living longer with cancer an increasing proportion of new cancer cases
occur in patients with a previous history of cancer. Approximately 19% of cancers
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diagnosed from 2005 to 2009 were not first cancers, compared with only 9% diagnosed
from 1975 to 1979 (American Society of Clinical Oncology, 2016). The National Cancer
Institute report as of January 2019, there were an estimated 16.9 million cancer survivors
in the United States and the number of cancer survivors is projected to increase to 22.2
million by 2030. The new development of treatment options allows the opportunity for
patients to live longer with cancer therefore increasing the incidence of cancer while
decreasing the mortality. Cancer is becoming more prevalent as the prognosis of cancer is
improving with the expansion of cancer treatment options.
Advancement of Chemotherapy
In 2015, the FDA added 15 new drugs and biologic therapies to its list of more
than 180 approved anticancer agents and expanded use for 12 previously approved
treatments (American Society of Clinical Oncology, 2016). The development of OAM
have revolutionized cancer treatment. The pipeline of oral oncology drugs is growing
with almost half of 300 medications in phase II and III clinical trials are oral medications
(Tipton, 2015). The standard of care for intravenous chemotherapy includes the patient
visiting an oncology practice or ambulatory infusion center to receive treatment. After
meeting with the oncologist, the patient would require a certified oncology nurse to
obtain intravenous access, perform a nursing assessment and then administer the
chemotherapy. The treatment is given in a safe, structured, and controlled environment
with providers on site. As a result of the transition from IV to oral form, the responsibility
of proper administration and medication adherence shifts from the oncology nurse to the
patient and or caregiver. This change in the treatment of cancer has led to new concerns
for patients and caregivers, healthcare providers, and healthcare systems (Tipton, 2015).
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The OAM is only therapeutic if the patient is taking the medication properly. Poor
adherence to OAM is consistently associated with worse disease outcomes, including
lower likelihood of response of therapy and a higher mortality (Greer et. al., 2016).
Challenges in Oral Chemotherapy Administration
Matthews and Caprera (2014) performed a study focusing on the challenges with
oral medication adherence. The authors conducted 17 educational in-service programs
with a roundtable discussion. The participants included about 200 oncology nurses,
infusion coordinators, advanced practice nurses involved in clinical care and in
supervisory positions, practice managers, pharmacists, and pharmacy industry
consultants. Preceding the in-service program, the participants were informally surveyed
regarding their current policies and procedures the educating patients prescribed oral
chemotherapy, how confident they felt in providing patient teaching for oral
chemotherapy if that was their responsibility, and what resources they used for selfeducation and patient education. During the roundtable discussion, the participants
identified the need for a user-friendly resource that includes essential information about
oral chemotherapy in a condensed chart.
Matthews and Caprera (2014) developed a new tool called the Essentials of Oral
Oncolytic Guide (EOOG). The main objective of this tool is to have a condensed
summary of useful information about current oral chemotherapy in a simple format. The
goal is to be a resource for oncology nurses and clinicians involved in the care for
patients prescribed an OAM. The study’s participants endorsed the EOOG tool as a brief
and concise summary of the medication to be utilized during patient education. The
authors emphasized an implication for practice is to enhance knowledge of specific oral
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oncolytic for the improvement of patient outcomes. The cancer care team can apply
EOOG in their practice especially in telephone triage as the tool includes pertinent needto-know information of each oral chemotherapy.
An article by D’Amato (2008) stated educating cancer care providers about the
issues and barriers to adherence is imperative. Educated providers can then communicate
this important information to their cancer patients. Using a shared decision-making
process, clinicians make decisions with patients, including discussion of patients’ values
and preferences with respect to their current situation. Involving the cancer patient in all
aspects of decision-making process have been shown to increase patient motivation and
adherence. The author highlighted numerous contributing factors impacting medication
adherence, therefore utilizing one approach is unlikely to be effective. The World Health
Organization, reports although patient-related factors certainly influence adherence,
factors beyond the patient’s direct sphere of influence are also reported to considerably
affect adherence, including socioeconomic-, therapy-, and condition-related, and health
system factors. The author endorses the use of a multidisciplinary team approach to
promote medication adherence in their cancer patient. The cancer care team consisting of
pharmacists, oncology nurses, behavioral specialists, and physicians has been shown to
improve patient adherence by facilitating patient related barriers to oral chemotherapy.
Another factor impacting oral chemotherapy administration is adverse side effects
from the OAM. Side effects of oral cancer therapies may be different from drugs
delivered via IV, but they have the same potential for severity, making patient education
and monitoring equally important in both settings. Symptoms can quickly escalate at
home, resulting in exacerbation of minor side effects into serious acute conditions and
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require admission to an inpatient unit for acute management (Winkeljohn, 2010). Patient
education provided at the initiation of treatment must include common side effects with
recommendation for symptom control. Since, patients prescribed an OAM are seen less
frequently compared to patients receiving IV regimens, it is crucial for all patients to
know when, who, and how to contact their healthcare providers during and after clinic
hours.
Benefits of Oral Chemotherapy
The landscape of cancer treatment is continuously expanding with the research
and development of new OAM. Tipton (2015) reports the expansion of treatment options
contributed to an improved understanding of genetic, genomics, and molecular changes
which led to the development and use of more targeted oral agents. This author
performed an overview of the challenges related to oral agents, advantages and
disadvantages of taking an OAM, and the impact of adherence. The article states an
estimated 25%-30% of all cancer agents in development are oral medications. The
preference of oral therapy often is related to convenience, avoiding the need for insertion
of central venous catheter or enduring the difficulties of poor peripheral IV access, and
being able take the oral medication at home (Tipton, 2015). The advantage of taking
OAM at home considerably decreases the need for transportation and length of stay at the
ambulatory infusion center when compared to IV chemotherapy.
The standard of care for patients receiving traditionally IV chemotherapy include
an office visit for an appointment with the oncologist and then treatment in the infusion
area. The length of time for the appointment with infusion will vary from one to eight
hours depending on the cancer type and treatment regimen, which may include multiple
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medications. The transition from IV to OAM offers many advantages to cancer patients
including greater flexibility and convenience, and less disruption of activities of daily
living for the patient and family or caregiver (Bellomo, 2016). Additionally, this offers
the patient the opportunity to return to work sooner when compared to traditional IV
chemotherapy. Furthermore, this is beneficial for the patients who depend on caregivers
for transportation because these patients are seen less in the office therefore requiring less
days off work for appointments for the caregivers. Tipton (2015) explained the
convenience and flexibility of taking the medication at home may have a positive impact
on the patient’s quality of life because less time will be spent in the clinic compared to
receiving traditional IV chemotherapy.
Disadvantages of Oral Chemotherapy
The article by Tipton (2015) described disadvantages as issues with adherence,
communication, bioavailability, and safety. The author identified issues with adherence
to OAMs can lead to several consequences, and may have a harmful impact on patient
outcomes. The concept of overadherence is imperative to emphasize in oncology care as
patients may take more medication than prescribed because of the misconception that
more medication will eradicate the cancer. This misunderstanding can lead to an increase
in serious adverse side effects, and negative outcomes. Since, the right drug is being
administered in the right amount and at the right time in a controlled setting is being
taken out of the hands of the oncologist and is being placed on the patient, family, or
caregiver (Bellomo, 2016).
The responsibility of medication adherence and monitoring for adverse side effect
transfers from the nurse to the patient. Consequently, if the patient is nonadherent to their
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OAM, this may lead to an undesirable impact on the efficacy of the OAM and overall
patient survival. Poor adherence also can affect outcomes such as patient satisfaction and
financial outcomes (Tipton, 2015). The author expressed effective and targeted
communication is critical for these patients and caregivers as they are seen less often in
clinic. Therefore, establishing a mode of communication between the care team is vital to
promote and monitor medication adherence.
Another disadvantage Tipton (2015) described the concern of bioavailability
because each medication has specific absorption characteristic with precise instruction on
how to take the medication with or without food, or if any drug to drug interaction, may
affect drug toxicity or efficacy. In respects to the medication bioavailability, patients
taking their medication unsupervised at home may lead to improper medication
administration which is a safety concern. For example, Palbociclib is an oral
chemotherapy indicated for the treatment of stage IV breast cancer. This medication
should be taken with food to assist with the absorption. If the patient is not taking the
medication as prescribed this may impact the efficacy of the medication and increase
toxicities.
Another disadvantage highlighted by the author is managing misconceptions that
OAMs are not perceived as powerful and hazardous materials. This misunderstanding can
lead to safety concerns including medication errors or improper safe handling of
chemotherapy. For example, mishandling of an OAM could lead to inadvertent physical
exposure of family members to hazardous substance and environmental contamination
(D’Amato, 2008).
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Oral Anticancer Medication Adherence
A systematic review by Atkinson et al. (2016) assessed the correlation between
patient-reported and objective oral anticancer medication adherence measures. The
authors identified significant challenges to accurately monitor patients taking OAM. The
study defined the objective measures of OAM adherence were a pill count, pharmacy fill
rates, and the use of a Medication Event Monitoring System (MEMS). This consists of an
electronic detection of package entry by incorporating micro-circuitry into
pharmaceutical packages of various design, which detects, time-stamps and stores the
maneuvers needed to remove a dose of the drug. The patient-reported measures utilized
in the study were the medication adherence rating scale and self-report survey. The
findings of the study revealed patient-reported OAM adherence rates were equal to or
higher than objective OAM adherence across the majority of studies. For example,
patients reported that they were adherent to their OAM by taking the medication as
prescribed, although when directly compared to the pharmacy fill rate, the OAM
prescription had not been filled.
The authors concluded the higher rates of adherence could be impacted by
overestimation of adherence. Patients may feel the social desirability to adhere to their
medication regimen to be deemed as the “good patient” leading to overinflation to
adherence rates. The associations found among adherence measurements is suggestive
that patient-reported adherence is a valid method for eliciting this important information
(Atkinson et al., 2016). Psychometric research on the efficacy and validity of patientreported outcomes further supports this viewpoint (Sadahiro et al., 2000). The study’s
findings provide insight that utilizing patient-reported measures may be indictive of
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adherence. However, every study reviewed demonstrated varying levels of medication
non-adherence. The authors concluded there are several factors contributing to poor
adherence, but one of the primary barriers was a lack of affective communication
between patients and providers (Atkinson et al., 2016). The authors recommended the
utilization of patient-reported measures with nurse led interventions to improve
adherence rates to OAM.
The implications for practice from this study indicate that cancer care teams are at
the forefront of the patient’s overall health care team; therefore, they can potentially be in
the position to help improve OAM adherence. The nursing role in medication teaching
may mitigate the disconnect in communication between patients and providers,
maximizing medication adherence (Atkinson et. al., 2016). The study’s findings suggest
that the implications for practice is the cancer care multidisciplinary team is in an ideal
position to optimize patient-provider communication and help educate the patient on the
importance of adherence.
Intervention Aimed to Improve Medication Adherence
A systematic review by Greer et al. (2016) assessed rates and correlates of
adherence to OAM and intervention aimed to improving adherence. The findings of the
study suggested benefit of a treatment monitoring program that included oncology nurses,
advanced practice providers, and multidisciplinary pharmaceutical care. The authors
highlighted that patients prescribed an OAM are seen less in the onsite clinic
emphasizing these patients will have less opportunities for the oncology nurse to perform
a nursing assessment. Subsequently, the authors recommendation was to provide follow
up care remotely via telephonically or electronically. The findings of the study further
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validated the importance of establishing a treatment monitoring program that could be
provided by the cancer care team which includes the nurse practitioner, oncology nurses,
and pharmacist.
Patient Perspective on OAM
A prospective research study conducted by Divakaruni et al. (2017) evaluated
young adult patients’ perceptions regarding medication education, adherence monitoring
processes, and identification of patient-reported facilitator and barriers to adherence.
More than 80% of patients reported receiving education before starting therapy that
included the planned duration and schedule of OAM, short- and long-term side effects,
and the purpose and goals of treatment. However, 24% of patients report not being
informed of proper storage, handling, preparation, administration, and disposal of oral
chemotherapy. The study’s finding highlights the importance of educating the patient and
their caregiver at the initiation of treatment providing information about safe handling
and storage.
Furthermore, 24% of patients reported they did not have a plan for a missed dose.
The American Society of Clinical Oncology and the Oncology Nursing Society
administration safety standards recommends a plan of care that includes instruction if
they skipped or miss a dose (Dillmon et al., 2019). The findings of the study are
concerning as the patients who are unaware of instructions for a missed dose of their
OAM have the possibility overadherence by doubling dose. Moreover, this demonstrates
a degree of non-adherence for missing a dose, or not taking the OAM at the prescribed
time. Previous literature has demonstrated the high rates of nonadherence in the young
adult population. For this reason, the involvement of family, caregivers, and others in the
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education process may provide additional support with a challenging disease state such as
cancer (Divakaruni et al., 2017).
The study found 10 out of 17 patients reported adverse side effects hinders their
adherence. The authors concluded that side effects should be monitored in every patient
to ensure tolerability or to determine the appropriateness of an agent if these effects
cannot be mitigated. The oncology nurse is in a unique position to provide early
intervention of symptom management that may positively impact adherence. The authors
stated previous literature demonstrates the young adult population have higher rates of
nonadherence; therefore, the involvement of the family and caregivers during the initial
educational session can improve adherence.
The authors also observed the need to close the communication gap between
providers and patients by utilizing an oncology pharmacist or nurses. The patients taking
their OAM at home have decreased communication with providers since they are seen
less in the outpatient clinic. Consequently, there may be a breakdown in communication
between the patient and provider. This study provides evidence of the importance of
initial patient education to increase OAM adherence.
Oncology Nurse Role
With the cancer treatment paradigm shifting from the use of infusion
chemotherapy administration in controlled, supervised clinical setting to the use of oral
chemotherapy self-administered by patient in the home setting, adherence to therapy and
symptom management become a challenge to ensure safe, quality care for cancer patients
(Bellomo, 2016). Having a designated nurse to perform follow up care for patient’s
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prescribed an OAM may improve patient safety and help bridge the communication
between the patient and provider.
Moody and Jackowski (2010) performed an exploratory research study to describe
the development of the oncology nursing role for patients receiving OAM in an
outpatient medical oncology setting. The authors hypothesized the implementation of the
oncology nurse may have an impact on patient care with the desired outcome to improve
medication safety and adherence for patients receiving an OAM. The role of an oral
chemotherapy nurse is to ensure adequate education and support for patients. This
designated oral chemotherapy nurse reviewed proper dosage, safe handling techniques,
recognition of critical side effects to report, dietary restrictions, drug interactions, and
medication adherence. Prior to the start of each treatment cycle patients are seen by the
nurse and they performed a nursing assessment and applied interventions as applicable,
allowing the oncology nurse an opportunity to address the side effects, adherence, and
provide support. Additionally, the designated oncology nurse conducted telephone triage
calls with these patients, which led to earlier interventions in managing common side
effects. The nurse documented the interaction in the medical record, which lead to
improved documentation of side effects. Nurses designated to care for people taking an
OAM can help patients and caregivers understand the importance of adhering to oral
chemotherapy regimens, recognize side effects and report immediately, and safely
administer and handle oral chemotherapy (Moody & Jackowski, 2010). The study’s
finding suggests the implementation of a designated oncology nurse to provide follow up
care for patients prescribed an OAM can have a positive impact on adherence, and
symptoms management.
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Advance Practice Nurse-led OAM Education
A randomized clinical trial by Schneider et al. (2014) developed a tailored nurse
coaching intervention to identify barriers to and facilitators of taking an OAM, and
working with patients to identify strategies that helped patients take medications as
prescribed. The study utilized advance practice nurses (APNs) to interview cancer
patients at the initiation of their OAM. During this visit the APNs obtained information
that may influence medication adherence. For example, cognitive function, the presence
of caregivers or support system, and health literacy. The APNs individualized a coaching
intervention based on the results of the assessment utilizing strategies to improve patient
knowledge, enhance behavior skills, and strengthen existing support systems. The control
group received the standard of oral chemotherapy education which included a disease
specific patient education notebook and instructions on their treatment provided by a
clinic nurse. The participants in the intervention group received standard of care in
addition to a personalized assessment and tailored intervention plan developed by an
APNs, and received weekly telephone follow up calls for the first month of the initiation
of treatment. After the first month, the telephone calls are twice a month for six months
or until discontinuation of medication.
The study found that the patients in the intervention group had higher rates of
adherence in both objective and subjective measures as compared to the control group.
The authors found a significant positive correlation between self-report and pharmacy
refill rate at the two-month time point. This supports the validity of using self-report as an
outcome measure in this study (Schneider et al., 2014). The oncology nurses can utilize
the patient reported measures to assess and monitor OAM adherence. Another finding of
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the study was that APNs were in a vital position for early intervention to mitigate
nonadherence by identifying critical barriers to adherence, like timely pharmacy
deliveries or preventing medication interaction. Schneider et al. (2014) concluded that the
use of APN to promote adherence helps patients manage symptoms and ensures the
medication are taken safely and properly. The study demonstrates the need to implement
a designated APN who will provide coaching intervention.
Patient’s Self-efficacy and OAM Adherence
A quasi-experimental study conducted by Tokdemir and Kav (2017) examined the
effects of a structured educational program on medication adherence and self-efficacy of
patients who were prescribed an OAM. Bandura (2001) defines self-efficacy is a person’s
belief in his or her ability to implement behaviors to achieve a desired outcome and
includes not only using the required to perform the behavior but also knowing how and
when to use them under diverse circumstances. The authors described self-efficacy as an
important feature that determines how individuals feel, thinks, and behaves. The authors
hypothesized individualized education increases patient medication adherence selfefficacy. The patients received education on proper administration, drug-specific
information, potential interactions, safe handling of the medication, plan for missed dose,
and importance of medication adherence by the researcher. Next, the nurse researcher
conducted telephone follow up calls at week one and two. During this call the researcher
assessed for side effects including nausea, vomiting, fatigue, lack of appetite, skin rashes,
constipation or diarrhea, dizziness, and oral mucositis.
The findings of the study indicated that the patients reported an increased selfefficacy on taking their OAM after the post-education compared to pre-education. The
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medication self-adherence scale reports an improvement from pre-education to posteducation, which demonstrated an increase in patient medication adherence. The findings
are significant and points to the importance of providing OAM education by a designated
provider at the initiation of treatment can improve patient medication adherence.
Additionally, the researchers found a reduction in symptom severity, and perceived
symptoms distress from the week one phone contact compared to week two phone
contact. In conclusion, a majority of patients (90.2%) reported they had not forgotten
their OAM; however, one third stated they did not believe that taking the drug has
positive outcomes, which is a risk factor for nonadherence (Tokdemir & Kav, 2017). In
response to these findings the indication for designating an oncology nurse to provide
education and support at the initiation of treatment increases the patient’s perceived selfefficacy in taking their OAM properly and safely.
White et al. (2019) performed an integrative review of current literature on the
self-efficacy for the management of symptom and symptom distress in adults with
cancer. The literature demonstrated a link between perceived self-efficacy for
management of symptoms, symptom distress, and quality of life. Bandura (2001) defines
perceived self-efficacy formulates the basis of any decision to act and is defined as the
perception of one’s own ability to implement behaviors to attain designated types of
outcomes such as symptom management. The authors identified the significance of
assessment of perceived self-efficacy at initiation of treatment is essential. The review
found that higher general self-efficacy was associated with higher symptom management
and lower symptom occurrence, symptom distress, improved performance outcomes, and
higher quality of life. Perceived self-efficacy for symptoms management can be learned,
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therefore the cancer care team is well positioned to assess the patient’s self-efficacy for
symptom management. The author describes the implication to practice is assessment of
self-efficacy for symptoms management starting at diagnosis and throughout the
treatment process would provide a guide for patient centered interventions. The cancer
care team should incorporate the patient centered interventions to assist with managing
symptoms related to cancer and it’s treatment.
The article identified several nurse-led interventions that are feasible and effective
for increasing perceived self-efficacy for symptom management and reducing symptoms
severity and distress. The interventions utilized by the nurses to enhance the patient’s
perceived self-efficacy were described and included direct mastery experience, vicarious
experience, social and verbal persuasion, and interpreting inferences from physiologic
and psychological (White et al., 2019). For example, many patients show signs of distress
when they are anticipating and experiencing alopecia. The nurse can implement the
efficacy-enhancing intervention of vicarious experience and social persuasion by
referring the patient to cancer survivor support groups and relaying experiences with
patients who have undergone distress from alopecia. The findings of the study revealed
the presence of high self-efficacy predicted higher physical and emotional well-being and
was associated with lower symptoms occurrence and symptom distress, which leads to
better overall health and improved quality of life (White et al., 2019).
The cancer care team are well positioned to recognize a knowledge deficit and
intervene with patient centered interventions to optimize OAM adherence. Further
indicating providing the cancer care team with a focused review of current literature with
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an educational presentation to identify and implement interventions to promote perceived
self-efficacy through patient education to enhance OAM adherence.
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Theoretical Framework
Bandura’s Self-Efficacy theory is a behavioral theory that is widely utilized in
nursing research and has been applied to several studies in oncology care. This behavioral
theory explains human behavior using concepts of self-efficacy and outcome
expectations. Bandura (1997) defines self-efficacy as a person’s belief in his or her ability
to implement behaviors to achieve a desired outcome and includes not only using the
skills required to perform a behavior, but also knowing how and when to use them under
diverse circumstances. The theory describes perceived self-efficacy as the patient’s
perception of ability to self-manage their care. Bandura (1997) has identified perceived
self-efficacy as a powerful mediator of health promoting behaviors which lead to
successful outcome attainment. An outcome expectation is defined as person’s estimate
that a given behavior will lead to a certain outcome (Bandura, 1997, p. 193). The theory
appraises the relationship between person’s environment, patient factors, cognitive
factors, behavior and how they interact and influence each other.
Bandura Self-Efficacy theory believes individuals formulate their self-efficacy by
appraising information from direct mastery and vicarious experiences, social/verbal
persuasion, and interpreting inferences from physiological and psychological states.
Direct mastery experience is defined as performing an activity, and vicarious experience
is observing other similar to oneself successfully performing an activity (Hoffman et al.,
2003). Social and verbal persuasion is defined as being influenced to believe in the
capabilities to achieve a goal. Interpreting inferences from physiological and
psychological states indicative of personal strengths and vulnerabilities to reach goals.
The cancer care team is forefront of care to assess the patient’s perceived self-efficacy for
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management of symptom and enhance their perceived self-efficacy by implementing
patient-centered interventions to assist with symptom management.
White et al. (2019) performed an integrative review on self-efficacy for the
management of symptom distress and concluded self-efficacy and symptom management
are vital concepts that affect outcomes for adults with cancer in all stages of treatment.
Patients prescribed an OAM are expected to self-manage their symptoms but may not
have the self-efficacy to do so. Therefore, providing the cancer care team with a focused
review of literature with an educational program including interventions to be utilized to
enhance the patient’s perceived self-efficacy. This theory is relevant to this quality
improvement project as the cancer care team is in a unique position to improve the
patient’s perceived self-efficacy through patient education.
The project will include the four concepts of Bandura’s Self Efficacy theory. The
PowerPoint presentation includes patient-centered intervention utilizing the concepts of
direct mastery experience, vicarious experiences, verbal persuasion, and physiological
and affective cues. The presentation include the relationship of perceived self-efficacy
and the management of symptoms with interventions to control symptoms to potentially
improve functional status and quality of life for adults with cancer.
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Method
Purpose
The purpose of this quality improvement project is to evaluate and expand the
cancer care team’s knowledge of oral anticancer medication. The aim is to expand their
knowledge by providing a focused review of literature with an educational program
derived from the American Society of Clinical Oncology (ASCO) and Oncology Nursing
Society (ONS) recommendations. The program includes identifying and implementing
interventions to improve the cancer care team knowledge, patient education and enhance
oral anticancer medication adherence.
Design
The design used will be a quality improvement project that includes a preeducation survey, then an educational program reviewing the best practice in patient oral
anticancer medication management, followed by a post-education survey.
Sample and Setting
The sample selection will be purposive sampling. The participants will be
recruited from Cancer Care Team at the Hematology & Oncology Associates of Rhode
Island. The author will invite nine staff members in the office including five registered
nurses, one nurse practitioner, one pharmacist, and two medical assistants. The targeted
sample size will be nine because of the limited amount of staff members in the office.
The participants will be given an informational document which will include the purpose,
and what data will be collected and how the data will be used. Participation will be on a
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voluntary basis. The director of the Hematology & Oncology Associates of Rhode Island
has given permission to conduct this project in the office during normal business hours on
a designated day preapproved by the clinical nurse manager (Appendix A). Inclusion
criteria are staff members who provide care to oncology patients prescribed an OAM,
includes registered nurses, nurse practitioner, pharmacist, and medical assistants.
Exclusion criteria are staff member who do not provide care to patients prescribes OAM.
Data Collection and Measurement
The data will be gathered in the form of a pre-education and post-education
survey total scores. The content of the survey questions will be developed based on the
best practice in OAM management. The survey questions will assess the participant’s
knowledge of an OAM. The questions will consist of six multiple choice and select all
that apply, and five questions in the format of a 5-point Likert scale. The pre-education
survey will be administered at the start of the designated time frame for the education
program. The participants will be given 15 minutes to complete the survey. The
participants will watch a 30-minute prerecorded educational PowerPoint presentation.
The educational program is derived from 2016 American Society of Clinical Oncology
(ASCO) and Oncology Nursing Society (ONS) administration safety standards (Neuss et
al., 2017)., include guidelines to identifying and implementing interventions to optimize
medication adherence, and to improve patient education. The participants will be given
15 minutes to complete the post-education survey at the end of the educational program.
The time frame for this quality improvement project will be approximately one hour long
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with 15 minutes to complete pre-survey, 30 minute educational program followed by a 15
minute post survey. The pre and post survey are in Appendix B.
Ethical Consideration
All participation was voluntary, and no incentives would be offered to
participants. There were no vulnerable population involved as the participants are staff
members in the Hematology & Oncology Associates of Rhode Island. The risks of
participation were no greater than that which is required of typical at-work in-service. A
brief statement accompanied the surveys to ensure the surveys were anonymous and
confidential. The pre and post surveys were collected at the conclusion of the project.
This project was be submitted and approved by the IRB at Rhode Island College.
The study was feasible as Spoelstra et al, (2017) used similar methods and sample
to evaluate the implementation of a nurse practitioner intervention to promote patient
medication adherence and symptoms management. There were no financial disclosures.
No identifiable data was be collected.
Plan for Analysis
The study used quantitative analysis and descriptive statistics to analyze the data.
Dissemination
The findings of the study was disseminated in a quality improvement project
poster at Rhode Island College School of Nursing and posted on the RIC Library digital
commons platform.
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Results
This quality improvement project was included to a total of nine participants form
a multidisciplinary cancer care team. The sample included five registered nurses, one
nurse practitioner, one pharmacist, and two medical assistants who completed the pre-test
and post-test. The test consisted of six knowledge-based questions utilizing true or false
format, multiple choice questions, and select all that apply. Five opinion-based statements
utilized a Likert scale to score the responses. The results of the knowledge-based pre-test
and post-test scores are displayed below for questions 1-5 in Figure 1, and the results in
percentages in Figure 2.
Figure 1. Comparison of Knowledge-based Pre-test and Post-test Scores
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Figure 2. Comparison of Knowledge-based Pre-test and Post-test Scores by Percent
Pre-test (n=9)

Post-test (n=9)

Question 1

100% (9/9)

100% (9/9)

Question 2

66% (6/9)

100% (9/9)

Question 3

100% (9/9)

100% (9/9)

Question 4

100% (9/9)

100% (9/9)

Question 5

100% (9/9)

100% (9/9)

The scores ranged from 66% to 100% out of a possible 100% for the pretest with
an average score of 93.2%. The post-test scores all participants received 100%. Questions
1-5 were scored as correct or incorrect for the purposes of data comparison. The test
questions are available for review in Appendix B. The pre and post-test scores were
analyzed for percent change following the educational intervention. Only question
number two was answered incorrectly by three participants in the pretest. This question
was in a true or false format, evaluating the participant’s knowledge of misconceptions
for OAM. The question was evaluating if the patient would adhere to their OAM because
their perception of the seriousness of their cancer diagnosis. The post-test scores of the
participants were 100 % as compared to 93.2% from the pre-test demonstrating an
positive improvement in responses. The improvement in post-test scores demonstrate the
educational intervention increased the participants knowledge-base on OAM adherence.
Question 6 was a select all that apply format. This question evaluated the
participant’s knowledge of interventions aimed to improve OAM adherence. The preeducation survey scores demonstrated a knowledge deficit as the results were
significantly lower than the post-test scores. The pre-test scores revealed a knowledge
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deficit as intervention B received 33%, and intervention C and D received 44% correct.
Pre and post-test scores were analyzed for a change following the educational
presentation. The scores revealed a significant increase in the participant’s ability to
identify interventions to promote OAM adherence. The participants correctly identified
interventions C and D on the post-education survey. Therefore validating the educational
presentation can be utilized to expand the cancer care team knowledge of interventions to
promote OAM adherence. Ultimately, the scores revealed improvement in responses as
all the participants post-test scores were 100%. The improvement in the pre and postsurvey scores suggest the educational presentation is a valuable method to educate the
cancer care team. The results for question number six of the knowledge-based pre-survey
and post-survey scores are displayed below in Figure 3, and the results by percentages in
Figure 4.
Figure 3. Comparison of Knowledge-based Pre-test and Post-test Scores for
Question 6
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Figure 4. Comparison of Knowledge-based Pre-test and Post-test Scores for
Question 6 in Percentages.
Question 6

Pre-test

Post-test

A

88% (8/9)

100% (9/9)

B

33% (3/9)

100% (0/9)

C

44% (4/9)

100% (9/9)

D

44% (4/9)

100% (9/9)

E

88% (8/9)

100% (9/9)

F

88% (8/9)

100% (9/9)

The next section of the survey were five questions evaluating the participants’
understanding of care provided to patients prescribed an OAM utilizing a Likert scale.
The questions were assessing the participants’ opinion-based on their knowledge, ability
to identify interventions, and their confidence level in providing care to patients taking an
OAM. The responses were measured by the percentage of participant’s responses from
the options of disagree, somewhat disagree, neither agree or disagree, somewhat agree,
and agree. The percentage was analyzed for each question. The results of opinion-based
questions 1-5 are displayed below in Figure 5 is the pre-survey results and Figure 6 is the
post-survey results. Pre and post survey questions are detailed in Appendix B.

Figure 5. Pre-Intervention Survey Opinion-Based Answers by Percentages and
Number of Participants (N=9)
Question #

Disagree

1
2
3
4
5

11% : 1
22 % : 2
22 % : 2
33% : 3
33% : 3

Somewhat
Disagree
33% : 3
11% : 1
33% : 3
0
11% : 1

Neither
11% : 1
0
0
11% : 1
11% : 1

Somewhat
Agree
33% : 3
55% : 5
33% : 3
44% : 4
22 % : 2

Agree
11% : 1
11% : 1
11% : 1
11% : 1
22 % : 2

32
Figure 6. Post-Intervention Survey Opinion-Based Answers by Percentages and
Number of Participants (N=9)
Question #

Disagree

1
2
3
4
5

0
0
0
0
0

Somewhat
Disagree
0
0
22% : 2
0
0

Neither
0
0
0
0
0

Somewhat
Agree
44% : 4
44% : 4
33% : 3
66% : 6
33% : 3

Agree
55% : 5
55% : 5
44% : 4
33% : 3
66% : 6

In review of pre-survey question one, the results revealed the participants had
varied responses. The question was evaluating the participant’s opinion of being
knowledgeable of ASCO/ONS chemotherapy and administration safety standards
interventions for OAM. The responses ranged from disagree (11%, n=1), somewhat
disagree (33%, n=3), neither (11%, n=1), somewhat agree (33%, n=3), and agree (11%,
n=1). The pre-survey results describe a knowledge deficit as 44% of the participants
report disagree or somewhat disagree for being knowledgeable. The post-survey
responses improved as all the participants agree or somewhat agree with being
knowledgeable following the educational presentation. The post-survey results were
somewhat agree (44%, n=4), and agree (55%, n=5). The improvement from the presurvey or post-survey results demonstrates the educational presentation is a valuable tool
to educate the cancer care team to enhance their knowledge of interventions to improve
OAM adherence.
Question one assessed the participants’ knowledge compared to question two
which evaluated the participants’ opinion of their ability to identify interventions to
improve OAM. The responses ranged from disagree (22%, n=2), somewhat disagree
(11%, n=1), somewhat agree (55%, n=5), and agree (11%, n=1). The pre-survey results
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revealed 66% of the participants agreed or somewhat agree with their ability of identify
interventions to improve OAM management. The pre-survey responses differ from
question one and two as 44% of the participants disagreed or somewhat disagreed in
being knowledgeable about OAM interventions. Compared to question two, 66 % of the
participants agreed or somewhat agreed in their ability to identify interventions. The postsurvey results for question two were somewhat agree (44%, n=4), and agree (55%, n=5).
The improvement in responses from the pre and post-survey indicate the educational
presentation can be utilized to further expanded the participants ability to identify
intervention.
Question three was assessing the participants’ confidence level in providing
patient education at the initiation of OAM. The pre-intervention survey revealed the
participants had various responses ranging from disagree (22%, n=2), somewhat disagree
(33%, n=3), somewhat agree (33%, n=3), and agree (11%, n=1). In review of the presurvey, 55% of the participants disagree or somewhat disagree feeling confident
providing patient education. Following the educational presentation, the results improved
as 33% somewhat agree and 44% agree demonstrating the presentation increased their
confidence in providing patient education. The two participants reporting somewhat
disagree were the medical assistants. Patient education is deferred to the other members
of the cancer care team of registered nurses, pharmacist, and nurse practitioner.
Question four was evaluating the participants’ opinion on their ability to identify
patient or treatment related factors influencing medication adherence. In review of the
pretest, the responses were disagree (33%, n=3), neither (11%, n=1), somewhat agree
(44%, n=4), and agree (11%, n=1). The post-survey results significantly improved as

34
66% somewhat agree and 33% agree with their ability to identify patient or treatment
related factors influencing OAM adherence. Following the presentation all the
participants increased their knowledge as the total scores post-survey results improved.
The participants who selected disagree in the pre-survey had progressed to somewhat
agree. Also, this was seen in the participants who selected somewhat agree then enhanced
to agree following the educational intervention. The results of the post-intervention
survey demonstrate that best practice in OAM focused education can be utilize to expand
the cancer care team’s knowledge, and increase their ability to identifying patient or
treatment related factors influencing OAM adherence.
Question five evaluated the participants’ confidence level in providing care to
patient’s prescribed an OAM. The pre-survey results revealed disagree (33%, n=3),
somewhat disagree (11%, n=1), neither (11%, n=1), somewhat agree (22%, n=2), and
agree (22%, n=2). These results illustrate 55% disagree or somewhat disagree with
feeling confident to provide care. In review of the pre-survey results, the responses
demonstrates low confidence level leading to an opportunity to educate the participants
on providing care to patients prescribed to an OAM. Following the presentation, the
scores considerably improved as 66% agree and 33% somewhat agree. The pre-survey
revealed 44% agree or somewhat agree, compared to the post-survey results were 100%
agree or somewhat agree. Question five’s post-survey results further validating the
educational presentation as a valuable tool to educate the multidisciplinary cancer care
team on OAM management.
The pre- survey results revealed the participants had variable responses. The
participants’ reports they disagree or somewhat disagree with being knowledgeable of
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OAM, the ability to identify interventions, and low confidence level in providing care. In
review of the post-test scores, the responses for each question considerably improved
following the educational presentation. This was confirmed as the participants’ responses
progress to somewhat agree or agree in the post-test. The only exception was question
three, which was evaluating the participant’s confidence in providing patient care. The
two participants who selected somewhat disagree were the two medical assistants. Patient
education is predominantly provided by the registered nurses, pharmacist, or the nurse
practitioner. Providing patient education is not within the medical assistant’s scope of
practice. Although, the medical assistants are valuable and play an active role within the
cancer care team. They are in a forefront of the cancer care team and should reinforcing
positive behaviors and interventions to promote OAM adherence. Educating all the
members of the cancer care team would be beneficial by utilizing best practice
interventions to support OAM adherence.
Next the summary and conclusions will be discussed.
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Summary and Conclusions
The literature has revealed the development of oral anticancer medications are
rapidly evolving with various new emerging treatment options. The advancement in
OAM is growing annually, accounting for 40%–50% of new cancer treatments in
development (U.S. Food and Drug Administration, 2021). The transition from IV to
OAM offers many advantages to cancer patients including greater flexibility and
convenience, and less disruption of activities of daily living for the patient and family or
caregiver (Bellomo, 2016). The preference of oral therapy often is related to convenience,
avoiding the need for insertion of central venous catheter or enduring the difficulties of
poor peripheral access, and being able to take the oral medication at home (Tipton, 2015).
The standard of care for intravenous chemotherapy is to be administered by a
registered oncology nurse in an ambulatory setting. During their infusion the patients
have an opportunity to communicate with the cancer care team at set intervals. These
patients have a provider appointment before, during, and after treatment. Throughout
these interactions the patients are objectively assessed by the cancer care team. The
standard of care for OAM treatment, includes the patient and caregivers will meet with
the cancer care team to discuss their treatment plan and provide patient education.
With the paradigm shifting from treatment in a controlled clinical setting to a
patient’s home has many benefits but is paired with potential challenges including issues
with adherence, communication, bioavailability, and safety. Most importantly, the
transfer of responsibility of medication adherence has shifted from the cancer care team
to the patient and or caregiver at home. The literature illustrates suboptimal adherence
can negatively affect treatment efficacy, disease outcomes, and overall survival while
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also increasing toxicities (e.g., from over adherence) and healthcare costs, which makes
support for adherence a critical clinical priority (Belcher et al., 2022). The expansion of
OAM treatment options reveals the need to improve strategies for assessment, patient
education, adverse side-effect management, and ongoing monitoring of care.
This quality improvement project utilized a focused review of literature with an
educational program derived from the American Society of Clinical Oncology (ASCO)
and Oncology Nursing Society (ONS) administration safety standards The project was
created using a pre-intervention survey, a 30 minute educational presentation, and a postintervention survey. The project was developed to evaluate and expand the cancer care
team’s knowledge of OAMs and interventions to promote medication adherence. The
program included identifying and implementing interventions to improve the cancer care
team knowledge, patient education to improve patient’s perceived self-efficacy and to
enhance OAM adherence. Discussing the importance of adherence may be beneficial
because it may spur those with poor adherence to improve it may encourage those with
good adherence to continue (Ruddy et al., 2009)
The participants were employed by the Hematology & Oncology Associates of
Rhode Island who provides direct care to patients prescribed an OAM. The nine
participants included five registered nurses, one nurse practitioner, one pharmacist, and
two medical assistants who completed the pre-test and post-test. This quality
improvement project was found to be beneficial as evident by the post-intervention
scores. The pre and post-survey scores for questions 1-5 were analyzed for improvement
and found post-survey scores were 100 % as compared to 93.2% demonstrating
improvement in knowledge of OAM management following the educational presentation.
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Question six evaluated the participant’s knowledge identifying interventions
aimed to improve OAM adherence. The pre-survey scores demonstrated a knowledge
deficit as the results were significantly lower than the post-survey scores. The scores
were analyzed for improvement and revealed a significant increase in the participant’s
ability to identify interventions to promote OAM adherence. The improvement in the pre
and post-intervention survey scores confirms the educational learning program derived
from 2016 ASCO and Oncology Nursing Society (ONS) administration safety standards
(Neuss et al., 2017) is a valuable tool to educate the cancer care team.
The next section of the survey consisted of five questions evaluating the
participants’ understanding of care provided to patients prescribed an OAM utilizing a
Likert scale. The questions were assessing the participants’ opinion-base on their
knowledge, ability to identify interventions, and their confidence level in providing care
to patients taking an OAM. The participants’ responses for the pre-intervention survey
were disagree or somewhat disagree with being knowledgeable of OAM, the ability to
identify interventions, and low confidence level in providing care. In review of the postsurvey scores, the responses for each question considerably improved following the
educational presentation. The participants’ responses improved to somewhat agree or
agree in the post-survey demonstrating the educational presentation expanded their
knowledge and confidence in providing care to patient prescribed an OAM. The postsurvey results are meaningful since increasing the participants’ knowledge in identifying
barriers to medication adherence and selecting appropriate interventions as applicable.
The literature revealed educating the cancer care team about the issues and barrier
to adherence is imperative as they can communicate and reinforce important information
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to their cancer patient (D’Amato, 2008). Providing the cancer care team with a focused
review of literature with an educational program derived from the American Society of
Clinical Oncology (ASCO) and Oncology Nursing Society (ONS) administration safety
standard recommendations to promote adherence is necessary to enhance their
knowledge. The significance of the cancer care team utilizing evidence-based
interventions to inform best practices for patients managing their treatment at home on
OAM to optimize patient care and support.
The cancer care team are in the unique position to promote optimal adherence in
patients prescribed an OAM. Establishing trust and communication, providing support
and education, instituting effective treatment plans, and providing effective follow-up
with patients all contribute to improve patient adherence rates with the intention to
improve outcomes (D’Amato, 2008). The improvement in the pre and post-survey scores
suggest the educational presentation is a valuable method to educate the cancer care team.
Next, recommendations and implications for future practice will be discussed
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Recommendations and Implications for Advanced Practice Nursing
The development of OAMs provide patients with recommended treatment in a
less invasive, more convenient form than traditional intravenous cancer therapies. The
paradigm change from in-person IV therapy to at-home oral therapy for many cancers
requires nurses and other healthcare professionals to develop systems to support patients
(Given, 2016). The literature revealed despite this shift in cancer care, healthcare systems
are only beginning to set standards and procedures to support patients on OAM regimens.
The standard procedure for intravenous chemotherapy is well developed while there are
no standards for OAM. Less contact with the cancer care team and fewer opportunities
for education on treatment and symptoms management, so patient faces the increase
responsibility of maintaining their own healthcare. The literature illustrated given the
frequency of contact with on-site clinician consultation may be lower with oral
medication then with infusion chemotherapy, much of the ongoing assessment of
symptoms, adverse effects, and adherence will need to occur remotely either
electronically or telephonically (Greer et al., 2016). Patients tasked with managing their
treatment at home leading to the risk of fragmented care.
Belcher et al., (2022) performed a systematic review on ONS guidelines to
support patient adherence to their OAM. The author explained the implication to practice
of an APRN or pharmacist to lead this change in practice. The APRN can identify
strategies such as a gap analysis using a quality improvement project approach can help
clinical sites to prioritize what needs to be changed and built in well-working structures
that already in place (Belcher et al., 2022). The APRN is at the forefront of patient care
and can effectively bridge the gaps of care by facilitating barrier to adherence. Patientrelated barrier, such as educational barrier and lack of understanding of the importance of
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the medication, potential side effects, and management of side effects can be mitigated by
the APRN.
ONS guidelines report an oral chemotherapy management program (i.e.,
standardized management and documentation of patients receiving OAMs) recently
reported significantly lower overall incidence of adverse events, decreased emergency
department visits and hospitalizations, and improved medication adherence (Belcher et
al., 2022). The APRN role in supervising the processes for prescribing, educating,
documenting, and monitoring follow up care for patients taking OAMs have been shown
to be valuable. Having a designated APRN for the oral chemotherapy management
program would be favorable to have identification of a single APRN may help promote
trust with patients and provide them with a single point of contact at the oncology office.
The APRN may alleviate the disconnect between the patient and oncologist, and can
assist with symptoms management.
The literature revealed the implication of an APRN would be beneficial to the
multidisciplinary cancer care team by providing leadership and comprehensive care to
patients prescribed an OAM to optimize medication adherence. Although no single
intervention has been proved to be the most clinically relevant, studies demonstrated that
multiple interventions are available. APRNs have the ability to identify a patient
experiencing problems with medication adherence, a follow up evaluation of the diverse
an often complex contributing factors will help guide recommendations to improve the
patient’s medication taking behaviors. The cancer care team, patient, and APRN can
collaborate to develop a plan of care with interventions tailored to meet the patient’s
individual needs as well as the type of medication.
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The APRN can apply interventions aimed at risk assessment, ongoing assessment
of adherence, and proactive follow-up to promote adherence. Further validating the use of
a dedicated provider as the best approach to operationalizing these recommendations into
the clinical infrastructure. The APRN can prioritizes what needs to be changed or
improved in their organization’s standard of care. Additionally, APRN can assist with
educating the cancer care team on how they should incorporate these interventions in
their clinical practice.
The utilization of an APRN is valuable to provide evidence-based interventions
and the development best practice for patients prescribed an OAM. Since these patients
are seen less in the clinic, they require supplementary support and effective
communication from the cancer care team to ensure optimal treatment adherence. The
APRN can be the dedicated provider to optimize patient care by identifying barriers to
optimal medication adherence and applying interventions aimed to improve patient care.
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Appendix B
Pre-Post Survey
1) A common patient misconception of oral anticancer medication is that it is less potent
comparatively to intravenous chemotherapy.
A. True
B. False
2) Some cancer patients adhere to their oral anticancer medication regimen based on their
perception of the seriousness of their cancer diagnosis.
A. True
B. False
3) The cancer care team may enhance perceived self-efficacy of oral anticancer medication
adherence and symptoms management through patient education.
A. True
B. False
4) Identify the factors that negatively influence oral anticancer medication adherence.
A. Healthcare system factors including cost of care, lack of insurance coverage, or
access to convenient and efficient clinic
B. Breakdown in communication between the patient and provider relationship.
C. Treatment-related factors including the complexity of treatment regimen, and
short- and long-term side effects.
D. All of the above.
5) Consequences of nonadherence to oral anticancer medication include:
A. Poor disease outcomes such as relapse or decreased survival time
B. Increased health care utilization
C. Lack of patient satisfaction
D. All of the above

2
6) Which of the following are include in the ASCO/ONS chemotherapy and administration
safety standards interventions aimed to improve oral anticancer medication adherence?
(Select all that apply)
A. Calendars or a daily medication checklist, and or a pill diary
B. The oncology nurse will call the patient when they should take their medication.
C. Electronic reminders including alarms on clocks, timers and smartphone
applications
D. Home psychological support
E. Patient and family education
F. Establishing routine, which includes drug administration
Please circle the corresponding number based your opinion of the following statements:
1. I am knowledgeable of ASCO/ONS chemotherapy and administration safety standards
interventions for oral anticancer medications.
1
Disagree

2
Somewhat Disagree

3
Neither

4
Somewhat Agree

5
Agree

2. I am able to identify interventions to improve oral anticancer medication adherence?
1
Disagree

2
Somewhat Disagree

3
Neither

4
Somewhat Agree

5
Agree

3. I feel confident in providing patient education at the initiation of oral anticancer
medication.
1
Disagree

2
Somewhat Disagree

3
Neither

4
Somewhat Agree

5
Agree

4. I am able to identify patient or treatment related factors influencing medication
adherence, and knowledge of interventions to improve medication adherence.
1
Disagree

2
Somewhat Disagree

3
Neither

4
Somewhat Agree

5
Agree

5. I feel confident in providing care for patients prescribed an oral anticancer medication.
1
Disagree

2
Somewhat Disagree

3
Neither

4
Somewhat Agree

5
Agree
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